Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...